The Effect of a Liraglutide on IVF in Obese PCOS

Launched by UNIVERSITY MEDICAL CENTRE LJUBLJANA · Nov 21, 2017

Keywords

ClinConnect Summary

Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, in particular when PCOS is linked to obesity. Obese PCOS has poor IVF outcomes associated with impaired oocyte and embryo parameters and morphology. The purpose of this pilot prospective study was to investigate the effect of the novel medical therapy (combination of metformin and liraglutide (COMBI)) in the specific infertile obese PCOS population. GLP-1 has been investigated in regulation of reproductive system in animal models. Current observations suggest that it directly regulates kisspeptin and GnRH ...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 18 years old to 38 years old
• • polycystic ovary syndrome (rotterdam criteria)
• • BMI of 30 kg/m² or higher
• • Infertility
• • Before IVF
• Exclusion Criteria:
• • type 1 or type 2 diabetes mellitus
• • history of carcinoma
• • Cushing's syndrome or congenital (non-classic) adrenal hyperplasia
• • personal or family history of MEN 2
• • significant cardiovascular, kidney or hepatic disease
• • the use of medications known or suspected to affect reproductive or metabolic functions
• • the use of statins, within 90 days prior to study entry no other ovarian pathology normal male semen